EXICURE, INC. (XCUR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US30205M3097
EXICURE, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -4.23 m USD |
| EBIT | -5.61 m USD |
| Net income | -4.95 m USD |
| Diluted EPS – continuing operations | -0.79 USD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About EXICURE, INC.
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
More stocks
- REGIONAL HEALTH PROPERTIES, INC (RHEPZ)
- BioCorRx Inc. (BICX)
- FULLNET COMMUNICATIONS INC (FULO)
- AMERICAS CARMART INC (CRMT)
- CENTURY CASINOS INC /CO/ (CNTY)
- AMERICAN SHARED HOSPITAL SERVICES (AMS)
- BTC Digital Ltd. (BTCT)
- T3 Defense Inc. (DFNS)
- Armlogi Holding Corp. (BTOC)
- Theriva Biologics, Inc. (TOVX)
- Sadot Group Inc. (SDOT)
- VOLITIONRX LTD (VNRX)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.